AI-generated analysis. Always verify with the original filing.
Interpace Biosciences reported Q4 and FY 2025 revenue of $9.2M and $38.7M with income from continuing operations of $22.8M and $25.0M driven by a one-time non-cash tax adjustment, alongside strong thyroid revenue growth.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exch
Financial Statements and Exhibits.** (d) Exhibits . | Exhibit Number | | Description | |---|---|---| | 99.1 | | Press Release, dated March 30, 2026. | | 104 | |